Adverse Event Reporting for Proton Pump Inhibitor Therapy: An Overview of Systematic Reviews

Otolaryngology - Head and Neck Surgery (United States)

Volumn 155, Issue 4, 2016, Pages 547-554

  Abramowitz, Jason ^a   Thakkar, Punam ^a   Isa, Arton ^a   Truong, Alan ^a   Park, Connie ^a   Rosenfeld, Richard M ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

proton pump inhibitor

Indexed keywords

PROTON PUMP INHIBITOR;

ADVERSE OUTCOME; CLOSTRIDIUM INFECTION; COMMUNITY ACQUIRED PNEUMONIA; DRUG EFFECT; HIP FRACTURE; HUMAN; INCIDENCE; INTESTINE INFECTION; META ANALYSIS; PEPTOCLOSTRIDIUM DIFFICILE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT DURATION; VITAMIN DEFICIENCY; CLOSTRIDIUM INFECTIONS; HIP FRACTURES; PNEUMONIA; RISK FACTOR;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HIP FRACTURES; HUMANS; PNEUMONIA; PROTON PUMP INHIBITORS; RISK FACTORS;

EID: 84989829163     PISSN: 01945998     EISSN: 10976817     Source Type: Journal    
DOI: 10.1177/0194599816648298     Document Type: Review

References (38)

1. Koufman JA,. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope. 1991; 101: 1-78.
2. Campagnolo AM, Priston J, Thoen RH, et al. Laryngopharyngeal reflux: diagnosis, treatment, and latest research. Int Arch Otorhino- laryngol. 2014; 18: 184-191.
3. Guo H, Ma H, Wang J,. Proton pump inhibitor therapy for the treatment of laryngopharyngeal reflux: a meta-analysis of randomized controlled trials. J Clin Gastroenterol. 2016; 50: 295-300.
4. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6: e1000097.
5. Shea BJ, Bouter LM, Peterson J, et al. External validation of a measurement tool to assess systematic reviews (AMSTAR). PLoS One. 2007; 2: e1350.
6. Chan WW, Chiou E, Obstein KL, et al. The efficacy of proton pump inhibitors for the treatment of asthma in adults: a meta-analysis. Arch Intern Med. 2011; 171: 620-629.
7. Chen S, Song X, Gao X, et al. Proton pump inhibitors and the risk of colorectal cancer: a meta-analysis. J Clin Gastroenterol. 2011; 45: 177.
8. Kwok CS, Yeong JK, Loke YK,. Meta-analysis: risk of fractures with acid-suppressing medication. Bone. 2011; 48: 768-776.
9. Kwok CS, Arthur AK, Anibueze CI, et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012; 107: 1011-1019.
10. Gralnek IM, Dulai GS, Fennerty MB, et al. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol. 2006; 4: 1452-1458.
11. Shukla S, Shukla A, Guha S, et al. Use of proton pump inhibitors and risk of Clostridium difficile -associated diarrhea: a meta-analysis. Gastroenterology. 2010; 138: S-209.
12. Eom CS, Jeon CY, Lim JW, et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011; 183: 310-319.
13. Eom CS, Park SM, Myung SK, et al. Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med. 2011; 9: 257-267.
14. Heidelbaugh JJ, Goldberg KL, Inadomi JM,. Adverse risks associated with proton pump inhibitors: a systematic review. Gastroenterol Hepatol. 2009; 5: 725-734.
15. Yu EW, Bauer SR, Bain PA, et al. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med. 2011; 124: 519-526.
16. Janarthanan S, Ditah I, Adler DG, et al. Clostridium difficile -associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012; 107: 1001-1010.
17. Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2004; 4: CD001960.
18. Moayyedi P, Soo S, Deeks JJ, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2011; 2: CD002096.
19. Deshpande A, Pant C, Pasupuleti V, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol. 2012; 10: 225-233.
20. Keszthelyi D, Penders J, Masclee AA, et al. Is microscopic colitis a drug-induced disease? J Clin Gastroenterol. 2012; 46: 811-822.
21. Sierra F, Suarez M, Rey M, et al. Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther. 2007; 26: 545-553.
22. Giuliano C, Wilhelm SM, Kale-Pradhan PB,. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol. 2012; 5: 337-344.
23. Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011; 106: 1209-1218.
24. Trikudanathan G, Israel J, Cappa J, et al. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis. Int J Clin Pract. 2011; 65: 674-678.
25. Hess MW, Hoenderop JG, Bindels RJ, et al. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther. 2012; 36: 405-413.
26. Leonard J, Marshall JK, Moayyedi P,. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007; 102: 2047-2056.
27. Ye X, Liu H, Wu C, et al. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2011; 23: 794-800.
28. Gyte GM, Richens Y,. Routine prophylactic drugs in normal labour for reducing gastric aspiration and its effects. Cochrane Database Syst Rev. 2006; 3: CD005298.
29. Nikfar S, Abdollahi M, Moretti ME, et al. Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. Dig Dis Sci. 2002; 47: 1526-1529.
30. Johnstone J, Nerenberg K, Loeb M,. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther. 2010; 31: 1165-1177.
31. Gibson PG, Henry RL, Coughlan JL,. Gastro-oesophageal reflux treatment for asthma in adults and children. Cochrane Database Syst Rev. 2003; 2: CD001496.
32. Niederman MS,. Community-acquired pneumonia: management controversies. Part 1: practical recommendations from the latest guidelines. J Respir Dis. 2002; 23: 10-17.
33. Guyatt G, Rennie D, eds. Users' Guides to the Medical Literature: A Manual for Evidence-Based Practice. Chicago, IL: AMA Press; 2002: 361-362.
34. Tryba M, Cook DJ,. Gastric alkalinization, pneumonia, and systemic infections: the controversy. Scand J Gastroenterol Suppl. 1995; 210: 53-59.
35. Lessa FC, Gould CV, Mcdonald LC,. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis. 2012; 55 (suppl 2): S65-S70.
36. Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB,. Incidence and mortality of hip fractures in the United States. JAMA. 2009; 302: 1573-1579.
37. Maggio M, Lauretani F, Ceda GP, et al. Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals. Bone. 2013; 57: 437-442.
38. Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016; 176: 238-246.